TrianglePUBLICATIONS · 36600653
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Immunother Cancer
- Publication date
- 2022 Dec
- First author
- Chesney J
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Chesney J
- type
- Author
- name
- Lewis KD
- type
- Author
- name
- Kluger H
- type
- Author
- name
- Hamid O
- type
- Author
- name
- Whitman E
- type
- Author
- name
- Thomas S
- type
- Author
- name
- Wermke M
- type
- Author
- name
- Cusnir M
- type
- Author
- name
- Domingo-Musibay E
- type
- Author
- name
- Phan GQ
- type
- Author
- name
- Kirkwood JM
- type
- Author
- name
- Hassel JC
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Chesney J
- type
- Author
- name
- Lewis KD
- type
- Author
- name
- Kluger H
- type
- Author
- name
- Hamid O
- type
- Author
- name
- Whitman E
- type
- Author
- name
- Thomas S
- type
- Author
- name
- Wermke M
- type
- Author
- name
- Cusnir M
- type
- Author
- name
- Domingo-Musibay E
- type
- Author
- name
- Phan GQ
- type
- Author
- name
- Kirkwood JM
- type
- Author
- name
- Hassel JC
- type
- Author
- bibliography ids
- nci-bib-391ff0b72b20db3a1f547919
- book metadata
- content sha256
- 234cd134ec98b32a841c27999d46929b57c8c008ab631c7ce482cfe76f719be0
- document type
- citation
- dois
- 10.1136/jitc-2022-005755
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:36600653
- immutable id
- pubmed:36600653@234cd134ec98b32a841c27999d46929b57c8c008ab631c7ce482cfe76f719be0
- journal
- abbreviation
- J Immunother Cancer
- issn electronic
- 2051-1426
- issn print
- Source null
- issue
- 12
- name
- Journal for immunotherapy of cancer
- nlm unique id
- 101620585
- pages
- Source null
- volume
- 10
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 36600653
- provenance
- batch id
- d370e99271168e8a8a13
- provider
- NCBI PubMed ESummary
- record sha256
- ee9b312deb2bdd910df267b8b799fb289a8961bca5689ad1a0beb115fb66ce17
- response sha256
- f65ace3ceb1efa86f3fbab8e01ce265243e7c6b7f13c5f71c357c1f219ad79c4
- retrieved at
- 2026-09-09T23:48:13.005737+00:00
- publication date
- display
- 2022 Dec
- precision
- month
- year
- 2022
- publication types
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Preserved source evidence · Not medical advice